Browse by category

Novo Nordisk has submitted a New Drug Application (NDA) to the FDA for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition. CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2

Novo Nordisk has entered into a definitive agreement to acquire Akero Therapeutics, a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (FGF21) analogue efruxifermin (EFX) is a potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH). EFX is currently in phase 3 development for the treatment of patient

Novo Nordisk has launched a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved...

Novo Nordisk and Septerna have announced an exclusive global collaboration and license agreement to discover, develop and commercialise...

The United Laboratories International Holdings Limited’s (TUL) wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd....

Novo Nordisk has announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor...

Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic...

Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...

Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...

GE HealthCare and Novo Nordisk are collaborating to further advance the clinical and product development of peripheral focused ultrasound...